Few tech companies have crashed and burned in recent years like Theranos, a blood-testing startup that claimed it would revolutionize healthcare by doing away with "big bad needles." But money moves fast in Silicon Valley, where the company began — and sometimes it moves too quickly for the ideas behind it to keep pace. In the case of Theranos, launched over a decade ago by Stanford drop-out Elizabeth Holmes, investors put hundreds of millions in a concept with little-to-no published science to support it.